Pregled bibliografske jedinice broj: 227348
Post-transplant lymphoproliferative disease (PTLD) in OLT patients in University Hospital "Merkur" Zagreb
Post-transplant lymphoproliferative disease (PTLD) in OLT patients in University Hospital "Merkur" Zagreb // Transplant International
Ženeva: Blackwell Publishing, 2005. str. 219-219 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 227348 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Post-transplant lymphoproliferative disease (PTLD) in OLT patients in University Hospital "Merkur" Zagreb
Autori
Čolić-Cvrlje, Vesna ; Naumovski-Mihalić, Slavica ; Kardum, Ika
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Transplant International
/ - Ženeva : Blackwell Publishing, 2005, 219-219
Skup
The 12th Congress of the European Society for Organ Transplantation
Mjesto i datum
Ženeva, Švicarska, 15.10.2005. - 19.10.2005
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
Tansplantacija jetre; PTLD; lymphoproliferative liver disease
(Liver transplantation; PTLD; lymphoproliferative disease)
Sažetak
PTLD is associated with EBV and CMV infection in SOT (solid organ transplantation). In University Hospital “ Merkur” Zagreb 108 liver transplantations have been performed. Two patients developed PTLD. The first was 54 years old men transplanted for HCV RNA cirrhosis Child C. 4 month after OLT he was CMV DNA positive and received ganciclovir 2x5mg/kg/twice daily 14 days i.v. and 3x1 gr. Peroral daily for 3 months. EBV DNA was negative. NHL-B cell lymphoma in abdominal lymph nodes was diagnosed and he received rituximab, but died within 2 months because of NHL progression. The other patient 56 old men was transplanted for alcoholic cirrhosis. 6 months after OLT CMC DNA was positive and the same schedule of ganciclovir was applicated. EBW DNA was negative. NHL-B cell lymphoma in liver graft and abdominal lymph nodes was diagnosed. He underwent rituximab and CHOP chemotherapy and is still alive. Conclusion: the risk of PTLD during the first year post-transplant in EBV negative, but CMV positive patients is higher even the therapy with ganciclovir was provided.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Napomena
Transplant International. 2005 ; 18 (Suppl. 1)
POVEZANOST RADA
Ustanove:
Klinička bolnica "Merkur"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE